Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 19, 2019

Genentech gets FDA nod for Tecentriq plus chemotherapy to treat ES-SCLC

Roche Group member Genentech has secured approval from the US Food and Drug Administration (FDA) for its Tecentriq (atezolizumab) in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Image: Genentech in South San Francisco, US. Photo: courtesy of F. Hoffmann-La Roche Ltd.